药品注册申请号:050574
申请类型:NDA (新药申请)
申请人:NOVARTIS
申请人全名:NOVARTIS PHARMACEUTICALS CORP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 SANDIMMUNE CYCLOSPORINE SOLUTION;ORAL 100MG/ML Yes Yes AB2 1983/11/14 1983/11/14 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2023/09/28 SUPPL-57(补充) Approval Labeling STANDARD
2016/07/14 SUPPL-52(补充) Approval Manufacturing (CMC) PRIORITY
2015/03/31 SUPPL-51(补充) Approval Labeling STANDARD
2014/01/22 SUPPL-49(补充) Approval Manufacturing (CMC) PRIORITY
2013/05/03 SUPPL-47(补充) Approval Labeling STANDARD
2012/08/30 SUPPL-43(补充) Approval Labeling STANDARD
2010/04/30 SUPPL-42(补充) Approval Labeling UNKNOWN
2009/10/08 SUPPL-41(补充) Approval Labeling UNKNOWN
2006/03/06 SUPPL-40(补充) Approval Labeling STANDARD
2005/07/19 SUPPL-39(补充) Approval Labeling STANDARD
2004/02/06 SUPPL-37(补充) Approval Labeling STANDARD
2004/02/06 SUPPL-35(补充) Approval Labeling STANDARD
2003/02/14 SUPPL-29(补充) Approval Labeling STANDARD
2003/02/14 SUPPL-27(补充) Approval Labeling STANDARD
2002/06/14 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
2002/04/12 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
2002/02/22 SUPPL-30(补充) Approval Manufacturing (CMC) PRIORITY
2002/01/16 SUPPL-31(补充) Approval Manufacturing (CMC) PRIORITY
2001/11/16 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
2000/10/04 SUPPL-25(补充) Approval Labeling STANDARD
1999/12/21 SUPPL-26(补充) Approval Labeling STANDARD
1999/05/13 SUPPL-24(补充) Approval Manufacturing (CMC) PRIORITY
1998/10/20 SUPPL-23(补充) Approval Manufacturing (CMC) PRIORITY
1998/07/27 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
1998/03/30 SUPPL-20(补充) Approval Manufacturing (CMC) PRIORITY
1998/01/30 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1996/08/09 SUPPL-18(补充) Approval Labeling STANDARD
1996/03/22 SUPPL-19(补充) Approval Manufacturing (CMC) PRIORITY
1995/11/21 SUPPL-17(补充) Approval Labeling STANDARD
1995/04/28 SUPPL-16(补充) Approval Manufacturing (CMC) PRIORITY
1995/03/07 SUPPL-14(补充) Approval Manufacturing (CMC) PRIORITY
1994/11/10 SUPPL-15(补充) Approval Labeling STANDARD
1994/05/19 SUPPL-13(补充) Approval Manufacturing (CMC) PRIORITY
1994/05/09 SUPPL-12(补充) Approval Manufacturing (CMC) PRIORITY
1994/05/09 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1993/03/19 SUPPL-10(补充) Approval Manufacturing (CMC) PRIORITY
1993/02/24 SUPPL-4(补充) Approval Manufacturing (CMC) PRIORITY
1993/02/16 SUPPL-3(补充) Approval Manufacturing (CMC) PRIORITY
1993/02/11 SUPPL-9(补充) Approval Manufacturing (CMC) PRIORITY
1992/02/21 SUPPL-8(补充) Approval Manufacturing (CMC) PRIORITY
1991/06/10 SUPPL-6(补充) Approval Labeling
1991/03/14 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1983/11/14 ORIG-1(原始申请) Approval Type 3 - New Dosage Form PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CYCLOSPORINE 剂型/给药途径:SOLUTION;ORAL 规格:100MG/ML 治疗等效代码:AB2
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050574 001 NDA SANDIMMUNE CYCLOSPORINE SOLUTION;ORAL 100MG/ML Prescription Yes Yes AB2 1983/11/14 NOVARTIS
065133 001 ANDA CYCLOSPORINE CYCLOSPORINE SOLUTION;ORAL 100MG/ML Discontinued No No AB2 2004/09/17 PHARMOBEDIENT CNSLTG
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database